,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc', 'bcsm', 'breast']
although already published, destiny breast 04 data are still stunning. t-dxd is effective in her2 low #mbc. the antibody-drug conjugate revolution just started. #bcsm #asco22 
Physician scientist, Breast Oncology @CroAviano, @Uniud, @LiquidBioTeam, @CtcLaboratory. #TranslationalResearch, #PrecisionMedicine, Mac Geek, Ramen Addicted.